Skip to main content

Table 1 Protein-tyrosine phosphatase (PTP) gene expression in Acute Myeloid Leukemia (AML) cells

From: Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression

  

RT-qPCR

Affymetrix

THP-1

EOL-1

MV4-11

RS4-11

  

n = 9

n = 206

n = 3

n = 3

n = 3

n = 3

 

Name

% Mean

SEM

Mean

SEM

% Mean

SD

% Mean

SD

% Mean

SD

% Mean

SD

A. Class Cys-Based PTPs

            

A.1. Classical PTPs

            

A.1.1. Transmembrane Classical PTPs

            
 

PTPRA

8.4

0.6

268.5

3.5

3.6

0.3

5.9

2.1

4.5

0.7

14.2

9.1

 

PTPRB

n.d.

 

26.5

0.9

n.d.

 

n.d.

 

n.d.

 

1.2

0.5

 

PTPRC

51.2

3.6

84.3

5.1

6.5

0.6

28.6

15.5

4.6

0.9

48.3

12.6

 

PTPRD

0.1

0.0

23.3

1.4

n.d.

 

n.d.

 

n.d.

 

n.d.

 
 

PTPRE

5.7

0.4

83.8

3.8

2.2

1.0

0.5

0.1

1.9

0.2

1.5

0.6

 

PTPRF

0.2

0.0

14.4

0.9

1.7

0.2

n.d.

 

n.d.

 

n.d.

 
 

PTPRG

n.d.

 

6.6

0.5

0.1

0.1

n.d.

 

0.5

0.0

0.1

0.0

 

PTPRH

4.0

0.3

18.3

0.8

0.1

0.1

n.d.

 

0.1

0.0

0.0

0.1

 

PTPRJ

3.1

0.2

26.4

1.7

4.1

0.7

1.9

0.3

1.7

0.7

1.2

0.3

 

PTPRK

n.d.

 

20.7

0.7

0.1

0.0

n.d.

 

n.d.

0.0

0.2

0.1

 

PTPRM

0.3

0.0

7.7

0.5

n.d.

 

n.d.

 

n.d.

 

n.d.

 
 

PTPRN

n.d.

 

56.9

1.4

n.d.

 

n.d.

 

n.d.

 

n.d.

 
 

PTPRN2

0.1

0.0

54.6

4.1

0.3

0.1

n.d.

 

0.2

0.1

0.1

0.0

 

PTPRO

n.d.

 

7.2

0.4

n.d.

 

n.d.

 

n.d.

 

n.d.

 
 

PTPRQ2

3.3

0.2

N.D.

N.D.

n.d.

 

n.d.

 

n.d.

 

n.d.

 
 

PTPRR

4.8

0.3

7.4

0.4

0.2

0.1

0.5

0.4

0.9

0.5

16.9

3.3

 

PTPRS

0.4

0.0

5.4

0.4

2.3

0.2

n.d.

 

n.d.

 

n.d.

 
 

PTPRT

n.d.

 

15.1

0.9

n.d.

 

n.d.

 

n.d.

 

n.d.

 
 

PTPRU

n.d.

 

64.8

1.5

0.2

0.1

0.1

0.0

0.1

0.0

n.d.

 
 

PTPRZ1

n.d.

 

8.9

0.5

n.d.

 

n.d.

 

n.d.

 

n.d.

 

A.1.2. NRPTPs

             
 

PTPN1

0.2

0.0

188.2

3.3

n.d.

 

0.1

0.1

n.d.

 

0.2

0.1

 

PTPN2

16.2

1.1

33.7

1.0

4.3

0.8

7.7

1.4

6.1

0.2

10.5

0.7

 

PTPN3

n.d.

 

26.5

1.0

0.3

0.1

n.d.

 

n.d.

 

n.d.

 
 

PTPN4

2.0

0.1

145.7

5.4

0.4

0.1

0.4

0.1

0.2

0.0

1.2

0.3

 

PTPN5

n.d.

 

2.8

0.1

n.d.

 

n.d.

 

n.d.

 

n.d.

 
 

PTPN6

43.4

3.0

1357.1

38.0

12.6

2.8

21.2

2.1

29.7

12.2

19.9

2.6

 

PTPN7

8.0

0.6

88.3

2.3

6.0

1.2

15.8

3.2

8.0

0.3

4.2

0.7

 

PTPN9

2.1

0.1

141.3

3.0

2.1

0.6

1.3

0.1

2.1

0.3

3.2

0.4

 

PTPN11

9.0

0.6

21.1

0.6

7.2

0.8

8.7

1.1

9.1

0.9

17.2

2.8

 

PTPN12

7.2

0.5

477.8

15.5

5.0

1.0

3.1

0.3

2.2

0.6

4.6

0.9

 

PTPN13

0.1

0.0

24.5

1.2

n.d.

 

0.5

0.2

n.d.

 

0.4

0.1

 

PTPN14

0.7

0.1

21.7

1.2

n.d.

 

0.1

0.1

0.6

0.2

3.8

0.4

 

PTPN18

0.6

0.0

30.6

1.4

0.1

0.0

0.1

0.0

0.3

0.1

0.2

0.0

 

PTPN21

n.d.

 

5.5

0.3

0.1

0.0

n.d.

 

n.d.

 

n.d.

 
 

PTPN22

44.6

3.1

248.7

7.4

5.8

1.5

5.1

0.9

3.6

1.7

4.4

1.0

 

PTPN23

6.0

0.4

32.9

1.0

2.0

0.7

1.4

0.2

1.4

0.1

2.7

0.5

A.2. DSPs or VH1-like

             

A.2.1. MKPs

             
 

DUSP1

85.1

5.9

4620.8

156.4

1.1

0.9

1.9

2.0

0.6

0.8

8.0

2.0

 

DUSP2

14.7

1.0

277.4

32.3

3.6

1.2

4.2

2.0

2.7

0.7

1.8

0.3

 

DUSP4

6.3

0.4

5.7

0.6

0.1

0.1

0.3

0.1

0.1

0.0

0.3

0.0

 

DUSP5

2.4

0.2

150.4

10.1

0.2

0.1

0.3

0.2

0.4

0.2

n.d.

 
 

DUSP6

52.2

3.6

1457.9

78.0

5.2

1.7

5.5

0.4

10.8

3.5

2.0

0.6

 

DUSP7

4.6

0.3

27.9

1.5

7.4

1.0

5.0

0.7

8.0

2.8

2.1

0.4

 

DUSP8

7.5

0.5

45.5

1.7

n.d.

 

n.d.

 

n.d.

 

0.1

0.1

 

DUSP9

1.1

0.1

18.3

0.7

0.2

0.1

0.1

0.0

n.d.

 

n.d.

 
 

DUSP10

10.5

0.7

335.2

14.2

0.6

0.4

2.8

0.4

1.2

0.5

1.3

0.3

 

DUSP16

0.6

0.0

74.1

2.5

0.6

0.2

0.1

0.0

0.1

0.1

0.9

0.4

 

MK-ST

5.4

0.4

131.1

3.1

3.3

0.4

2.0

0.1

4.7

0.7

6.8

1.9

A.2.2. Atypical DSPs

             
 

DUSP3

5.0

0.4

502.8

16.5

3.8

0.2

5.9

1.2

5.1

1.1

1.6

0.4

 

DUSP11

3.5

0.2

239.3

4.7

0.7

0.1

1.4

0.2

1.1

0.1

2.7

0.1

 

DUSP12

6.9

0.5

211.2

3.0

4.4

0.4

5.7

1.1

4.1

0.3

7.3

2.2

 

DUSP14

5.4

0.4

114.4

3.4

1.0

0.1

2.0

0.3

1.1

0.1

2.2

0.3

 

DUSP15

2.4

0.2

26.7

0.9

0.1

0.1

n.d.

 

n.d.

 

0.8

0.2

 

DUSP18

1.1

0.1

9.3

0.4

0.1

0.0

0.1

0.0

0.1

0.0

0.2

0.1

 

DUSP19

0.2

0.0

16.8

0.8

0.1

0.0

0.1

0.0

0.1

0.0

0.9

0.1

 

DUSP22

3.1

0.2

317.9

6.8

0.3

0.2

1.0

0.2

1.1

0.3

5.6

1.0

 

DUSP23

6.5

0.5

86.2

3.1

3.5

0.0

2.5

0.3

2.9

0.4

4.7

0.5

 

EPM2A

4.4

0.3

89.4

2.0

0.3

0.1

0.6

0.0

0.4

0.1

1.5

0.4

 

PTPMT1

7.8

0.5

128.2

3.1

3.3

0.3

3.9

0.4

4.3

0.3

8.2

0.8

 

RNGTT

1.9

0.1

162.4

2.4

1.4

0.3

2.2

0.5

1.5

0.2

2.7

0.3

 

STYX

5.3

0.4

279.5

5.3

4.1

0.4

4.1

0.8

5.1

0.6

6.4

1.2

A.2.3. Slingshots

             
 

SSH1

1.5

0.1

45.9

1.4

0.5

0.1

0.8

0.1

0.5

0.0

0.6

0.1

 

SSH2

7.6

0.5

48.5

2.0

1.9

0.3

3.0

1.1

2.5

0.4

4.6

0.9

 

SSH3

1.6

0.1

143.0

3.5

1.0

0.1

0.9

0.3

1.0

0.1

1.1

0.2

A.2.4. PRLs

             
 

PTP4A1

18.8

1.3

444.3

14.3

17.2

1.3

19.4

4.8

8.9

1.4

39.8

6.5

 

PTP4A2

50.2

3.5

1323.2

32.7

21.2

2.4

28.8

2.7

22.1

3.4

31.8

7.3

 

PTP4A3

1.6

0.1

92.2

7.7

0.2

0.1

1.5

0.0

1.7

0.4

0.2

0.0

A.2.5. CDC14s

             
 

CDC14A

3.1

0.2

98.2

2.9

1.3

0.2

1.0

0.3

0.9

0.1

1.2

0.3

 

CDC14B

n.d.

 

25.0

1.0

0.2

0.0

n.d.

 

0.1

0.0

n.d.

 
 

CDKN3

1.3

0.1

103.6

6.3

1.1

0.3

2.4

0.5

1.9

0.7

3.4

1.1

 

PTP9Q22

0.3

0.0

8.2

0.5

0.2

0.0

0.1

0.0

0.4

0.0

0.6

0.1

A.2.6. PTENs

            
 

PTEN

12.3

0.9

641.8

13.4

5.4

1.0

5.4

1.4

9.4

1.8

8.5

2.2

 

TNS1

2.3

0.2

16.2

2.7

0.5

0.0

n.d.

 

0.6

0.3

0.7

0.4

 

TNS3

2.0

0.1

305.5

12.6

1.1

0.2

2.7

0.9

1.1

0.1

0.5

0.1

 

TENC1

n.d.

 

31.5

1.4

n.d.

 

n.d.

 

n.d.

 

n.d.

 

A.2.7. Myotubularins

             
 

MTM1

1.6

0.1

109.4

2.1

1.0

0.2

1.2

0.5

0.8

0.1

0.6

0.1

 

MTMR1

0.8

0.1

316.0

6.4

0.6

0.2

0.7

0.2

0.3

0.0

0.8

0.1

 

MTMR2

3.1

0.2

201.8

5.3

3.5

0.2

3.2

0.2

3.1

0.1

6.9

0.5

 

MTMR3

3.3

0.2

272.5

6.7

1.5

0.4

0.7

0.1

0.9

0.3

2.9

0.8

 

MTMR4

2.0

0.1

222.9

3.8

2.9

0.5

1.8

0.1

1.3

0.2

5.8

0.1

 

MTMR5

8.6

0.6

12.1

0.8

1.9

0.6

2.6

0.3

2.6

0.4

6.0

1.6

 

MTMR6

2.2

0.2

326.6

10.1

1.5

0.1

3.2

0.9

1.3

0.2

2.1

0.3

 

MTMR7

n.d.

 

12.0

0.5

n.d.

 

n.d.

 

n.d.

 

n.d.

 
 

MTMR8

0.1

0.0

20.4

0.6

0.1

0.0

0.1

0.0

0.1

0.0

n.d.

 
 

MTMR9

1.5

0.1

113.9

2.7

1.2

0.1

1.4

0.3

1.7

0.3

1.7

0.4

 

MTMR10

2.6

0.2

14.6

1.1

1.4

0.2

1.1

0.2

1.1

0.3

4.8

1.1

 

MTMR11

n.d.

 

88.8

10.7

n.d.

 

n.d.

 

n.d.

 

n.d.

 
 

MTMR12

3.9

0.3

103.4

1.8

2.0

0.2

2.4

0.4

2.4

0.3

8.0

1.5

 

MTMR13

1.0

0.1

118.5

5.3

0.2

0.1

0.4

0.1

0.2

0.1

1.8

0.6

B. Class II Cys-Based PTPs

            
 

ACP1

24.5

1.7

18.7

0.7

11.9

1.1

21.5

1.8

18.1

0.9

52.7

2.6

C. Class III Cys-Based PTPs

            
 

CDC25A

0.9

0.1

67.3

3.4

2.6

0.2

2.9

0.3

1.8

0.7

4.3

1.0

 

CDC25B

2.5

0.2

285.0

11.3

0.4

0.1

2.2

0.4

1.8

0.1

2.4

1.0

 

CDC25C

0.4

0.0

44.4

1.8

0.4

0.1

0.8

0.1

0.9

0.1

1.0

0.3

  1. mRNA expression of 92 members of the PTP family was assessed by RT-qPCR analysis in AML patient primary cells (duplicate determinations of the indicated sample number, means in % of 3 housekeeping genes ± SEM). For comparison, PTP mRNA expression data for AML patient blasts were retrieved from an Affymetrix analysis (means ± SEM). PTP gene expression was also analyzed by RT-qPCR in four AML cell lines (3 experiments with duplicate determinations, means in % of 3 housekeeping genes ± SD). The 25% highest values in the respective sample type are highlighted in bold. n.d. – not detectable. Names of PTPs, which fall in this category in at least two different sample types, or only in one sample type, are labeled bold or by underlining, respectively. Classification was taken from Alonso et al. [21].
Back to article page

Cell Communication and Signaling

ISSN: 1478-811X